Viome is a precision nutrition company that aims to prevent and reverse chronic diseases by digitizing and decoding each individual's biology, starting with the gut microbiome. They analyze RNA (gene expression) to gain a comprehensive understanding of an individual's body and provide personalized food recommendations and made-to-order supplements. Viome is focused on advancing precision diagnostics and therapeutics for chronic diseases, cancer, and aging.

Naveen Jain

John Pinelli

Viome

Evvy offers an at-home vaginal microbiome test and clinical care options, focusing on vaginal health. It is self-described as the first and only CLIA-certified, mNGS vaginal health test.

Evvy

Longevity Circuit offers nutritional plans, astrological information, and supports a longevity lifestyle. The company has been involved in astrology for over 35 years, focusing on personal horoscopes and their potential benefits.

Longevity Circuit

Spoon Guru provides a platform that enhances product discovery in grocery shopping through AI and personalized recommendations, addressing dietary and lifestyle needs.

Spoon Guru

Viome | A Viome Life Sciences, Inc. Company.

We provide the industry’s only direct-to-consumer healthcare test that analyzes microbial and human gene expressions (mRNA), with technology exclusively licensed from Los Alamos National Lab, in order to provide individuals with health insights and the nutrition they need.

By joining Viome, you are joining a revolutionary movement. A movement that – for the first time in human history – will make becoming ill a matter of choice, and not simply bad luck.

Scientists have worked for over a decade to develop this technology that offers unprecedented visibility into your body. With this, we can create a unique profile of the biochemistry and ecosystem inside of you, and make personalized, actionable, and adaptive recommendations for your health.

Our at-home tests are not just one-time tests, but your true health companion, enabling you to monitor your health over time. Your results and recommendations adapt to your changing ecosystem so you are always aware and taking action towards maximizing your vitality and lifespan.

The Viome team is made up of scientists, engineers, researchers and entrepreneurs who are passionate about radically improving the wellness of our customers.

Bold Capital Partners

Khosla Ventures

Physician Partners

Hambrecht Healthcare Growth Venture Fund

Nomad Capital Partners

Marc Benioff

Matthew Harris

WestRiver Group

Ezaki Glico

Ocgrow Ventures

🎉 Wrapping up National Dental Hygiene Month and National Orthodontic Health Month with a Milestone! 🎉

As October concludes, it's not just the commitment to dental and orthodontic health that we celebrate but also the advancements in science that have the power to transform lives. Today, we're especially proud to highlight Viome's CancerDetect Test for Oral & Throat.

🔍 Here's why this is a game-changer:

✅ Breakthrough Technology: The FDA granted the breakthrough device designation to the technology behind CancerDetect. The technology behind CancerDetect is the same cutting-edge technology that powers Viome's Intelligence wellness tests. The breakthrough designation helps the FDA identify new technology to focus on in order to expedite access to novel devices that will save lives and treat debilitating diseases. The Breakthrough Program's purpose is clear: to ensure patients have swifter access to life-changing medical devices by hastening their journey from development to patient use.

✅ First of Its Kind Early Detection: CancerDetect is the first-ever test to identify biomarkers associated with oral and throat cancers with unmatched accuracy, including early stages, with a specificity of 95% and a sensitivity of 90%.

✅ Addressing a Critical Gap: Designed primarily for individuals at a higher risk of these cancers, CancerDetect addresses an urgent need for innovative solutions. Early detection is pivotal; when these cancers are diagnosed in the early stages, the 5-year survival rate can soar to 84%, a stark contrast to the sobering statistics of less than 50% when detected late.

In the spirit of National Dental Hygiene & Orthodontic Health Month, we not only emphasize the importance of regular oral care but also champion early detection and timely intervention. CancerDetect™ is redefining the future of oral and throat cancer diagnosis and treatment.

Learn more: https://www.viomepro.com/

To everyone involved in its development and to those who will benefit from it - here's to a brighter, healthier tomorrow! 🌟 #NationalDentalHygieneMonth #NationalOrthodonticHealthMonth #CancerDetect #OralMicrobiome #OralHealth #EarlyDetectionMatters

Viome is committed to our mission: envisioning a world where chronic illness becomes a matter of choice, not fate. We recognize the enormity of this challenge and its complexities, yet we are confident that by bringing the best minds together, we can significantly reduce the impact of chronic diseases. We're privileged to have the backing of eminent scientists and physicians who champion Viome's effort to push microbiome science and technology forward.

The new Oral Health Pro with CancerDetect from Viome can help #dental professionals detect markers for oral cancers and other oral and systemic conditions. https://lnkd.in/g7KCkY8N

The new offering relies on Viome's proprietary RNA sequencing technology and AI to identify early biomarkers associated with oral and throat cancers

Metric
Company Name	Viome	Evvy	Longevity Circuit	Spoon Guru
Symbol
MSH ID	COM:VIOME	COM:EVVY	COM:LCIRCUIT	GURU:SPOON
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Biotechnology	Healthcare & Health Services	Consumer Services	Consumer Services
Industry	Healthcare	Medical Diagnostics	Wellness and Lifestyle	Grocery Technology
Country	US	US	US	GB
Stage	Series D
Employee Count	101
Website	viome.com	evvy.com	lcircuit.com	spoon.guru
LinkedIn	viome		l-l-circuit-solutions-llc	spoonguru
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	192.38K	1.17K
Web Traffic Growth	-0.42	6.79
Valuation
Raised Capital	25M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:VIOME

Viome

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue